-
Nurix Therapeutics 2026 annual meeting votes: directors elected, auditor ratified, say-on-pay approved
Elected all three Class III director nominees: Arthur T. Sands (63.6M for, 16.3M withheld), Roger Dansey (79.6M for, 0.3M withheld), Paul M. Silva (59.3M for, 20.6M withheld).
-
Nurix Q1 net loss $87.2M ($0.79); advancing bexobrutideg registrational program
Revenue $6.3M vs $18.5M YoY; net loss $87.2M ($0.79) vs $56.4M ($0.67).
-
Nurix Therapeutics ups ATM equity offering capacity to $413.65M
Amendment No. 3 to Equity Distribution Agreement with Piper Sandler dated March 6, 2026.
-
Nurix reports FY2025 net loss of $264.5M; initiates DAYBreak registrational program for bexobrutideg
FY2025 revenue $84.0M (+54% YoY); net loss $264.5M ($3.05/sh) vs $193.6M ($2.88/sh) last year.
-
Nurix outlines bexobrutideg pivotal CLL plan, 83% ORR, $664M cash at JPM
Phase 2 DAYBreak CLL-201 enrolled Oct 2025; confirmatory Phase 3 vs pirtobrutinib planned in 2026.
-
Nurix releases Phase 1 CLL/SLL data: 83% ORR, 22.1mo PFS; WM ORR 75.0% at ASH 2025
Phase 1a CLL/SLL ORR 83.0% (47 evaluable), including 4.3% complete responses; median PFS 22.1 months, DOR 20.1 months.
-
Nurix appoints former Pfizer oncology chief Roger Dansey to board
Dr. Dansey appointed effective Nov 6, 2025, as Class III director and member of Clinical and Commercialization Committee.
-
Nurix raises $250M in registered offering; shares priced at $10.21
Offering of 24,485,799 shares at $10.21/share; gross proceeds $250.0M, net ~$234.3M.
-
Nurix initiates pivotal Phase 2 DAYBreak trial of bexobrutideg in r/r CLL with 600 mg QD dose
DAYBreak Phase 2 will enroll ~100 r/r CLL/SLL patients after prior cBTKi, ncBTKi, and BCL-2i; primary endpoint is ORR by IRC.
-
Nurix Q3 FY2025 net loss $86.4M ($1.03/share); cash $428.8M; bexobrutideg pivotal trials on track
Revenue $7.9M vs $12.6M YoY; net loss $86.4M ($1.03/sh) vs $49.0M ($0.67/sh) YoY.
-
Nurix begins investor meetings with updated clinical plans for bexobrutideg Phase 1 trial
Company presenting updated development plans for bexobrutideg (NX-5948), an oral BTK degrader.
-
Nurix director Lori Kunkel resigns; Roy Baynes named committee chair
Director Lori A. Kunkel, M.D. resigns from Board and committees effective September 1, 2025.
-
Nurix Q2 FY2025 revenue $44.1M (+264% YoY); Sanofi extends STAT6 license; bexobrutideg 80.9% ORR in CLL
Revenue $44.1M (vs $12.1M YoY) driven by $30M Sanofi license extensions and $5M Gilead milestone.
-
Nurix bexobrutideg shows 80.9% ORR in CLL, 84.2% in WM; pivotal trials on track for 2025
ORR 80.9% in CLL/SLL (n=47 evaluable); median time to first response 1.9 months; one complete response after >2 years.
-
Nurix Therapeutics annual meeting elects directors, ratifies auditor, passes say-on-pay
All three Class II director nominees elected: Reinsdorf (43.57M for), Saltzman (50.30M for), Baynes (60.82M for).
-
Nurix posts Q1 FY2025 net loss $56.4M; bexobrutideg gets orphan drug designation
Revenue $18.5M, up from $16.6M YoY; net loss $56.4M ($0.67/share) vs $41.5M prior year.
-
Nurix appoints former Merck CMO Roy Baynes to board of directors
Appoints Roy D. Baynes (EVP & CMO of Eikon, former Merck CMO) as Class II director, effective March 11, 2025.
-
Nurix Therapeutics reports FY2024 net loss $193.6M, cash $609.6M; NX-5948 ORR 75.5%
Revenue of $54.5M in FY2024, down from $77.0M YoY; net loss $193.6M ($2.88/share) vs $143.9M ($2.65) prior year.
-
Nurix reports preliminary cash $609.6M; plans pivotal CLL trials for NX-5948 in 2025
Preliminary cash and investments $609.6M as of Nov 30, 2024; runway into H1 2027.
-
Nurix: NX-5948 Phase 1 CLL/SLL shows 75.5% ORR, deepens to 84.2%; safe; pivotal trials in 2025
ORR 75.5% (n=49) in heavily pretreated CLL/SLL; 84.2% in patients with at least 2 assessments.
-
Nurix Therapeutics files $300M at-the-market stock offering via Piper Sandler
Amendment No.2 to Equity Distribution Agreement authorizes up to $300M aggregate gross offering price of common stock in ATM offerings.
-
Nurix appoints drug commercialization veteran Anil Kapur to board of directors
Appointed Anil Kapur as Class I director effective Oct 15, 2024, with term expiring at 2027 annual meeting.
-
Nurix Therapeutics reports Q3 FY2024 net loss $49M, $0.67 per share; cash $457.5M
Net loss $49.0M ($0.67 per share) vs $37.0M ($0.68 per share) in Q3 FY2023.
-
Nurix to present updated Phase 1 NX-5948 data at investor meetings starting Sept 5
Company began investor roadshow on September 5, 2024, with an updated investor slide deck.
-
Nurix posts Q2 net loss $44.5M; cash rises to $452.5M; NX-5948 ORR 69.2% in CLL
Net loss $44.5M ($0.71/sh) vs $24.3M ($0.45/sh) YoY; collaboration revenue $12.1M (+13% YoY).
-
Nurix Therapeutics: NX-5948 achieves 69.2% ORR in Phase 1 CLL; pivotal trial planned for 2025
Objective response rate of 69.2% in 26 evaluable CLL patients across 50-600 mg daily doses; responses deepened over time.
-
Nurix Therapeutics annual meeting: stockholders elect directors, ratify auditor, approve say-on-pay
Stockholders elected directors Julia P. Gregory (29.9M for, 4.5M withheld) and David L. Lacey (27.1M for, 7.3M withheld) to terms expiring 2027.
-
Nurix prices upsized $175M public offering of 10.17M shares and prefunded warrants at $15.00/share
10,166,667 common shares at $15.00/share plus 1,500,100 pre-funded warrants at $14.999/warrant.
-
Nurix Therapeutics Q1 FY2024 revenue $16.6M, net loss $41.5M; Gilead collaboration extended
Revenue $16.6M (up 31% YoY); net loss $41.5M ($0.76/sh) vs $40.7M ($0.75/sh) prior year.
-
Nurix announces first clinical responses in brain for BTK degrader NX-5948
NX-5948 detected in CSF from all available samples, showing brain penetration.